Showing 1 posts of 1 posts found.
Teva has appointed Dr Michael Hayden as its new president of global R&D and chief scientific officer at the firm’s …
London secures major investment to accelerate healthcare innovation
People with severe mental illness more likely to die early from cardiovascular disease, report finds
Yourgene wins Australian approval for chemotherapy toxicity screening assay
ProBioGen secures extended GMP authorisation for viral manufacturing facility
PlaqueTec coronary disease trial reaches 100 patients across eight NHS centres